Correlations between IL-6 serum level and olfactory dysfunction severity in COVID-19 patients: a preliminary study.

Anosmia COVID-19 Coronavirus Cytokine Cytokine storm IL-6 Interleukin 6 SARS-CoV-2 Smell

Journal

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 28 02 2021
accepted: 03 05 2021
pubmed: 14 5 2021
medline: 1 2 2022
entrez: 13 5 2021
Statut: ppublish

Résumé

Interleukin 6 (IL-6) is a proinflammatory cytokine that is secreted by cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and it is widely recognized as a negative prognostic factor. The purpose of this study was to analyze the correlations between the olfactory scores determined by psychophysical tests and the serum levels of IL-6 in patients affected by coronavirus disease 2019 (COVID-19) METHODS: Patients underwent psychophysical olfactory assessment with Connecticut Chemosensory Clinical Research Center test and IL-6 plasma level determination within 10 days of the clinical onset of COVID-19. Seventy-four COVID-19 patients were included in this study. COVID-19 staged as mild in 34 patients, moderate in 26 and severe in 14 cases. There were no significant differences in olfactory scores across the different COVID-19 severity groups. In the patient series, the median plasma level of IL-6 was 7.7 pg/mL (IQR 3.7-18.8). The concentration of IL-6 was found to be significantly correlated with the severity of COVID-19 with a directly proportional relationship. The correlation between IL-6 plasma concentrations and olfactory scores was weak (r In COVID-19 patients, psychophysical olfactory scores did not show significant correlations with the plasma levels of a well-recognized negative prognostic factor such as IL-6. This observation casts some shadows on the positive prognostic value of olfactory dysfunctions.

Sections du résumé

BACKGROUND BACKGROUND
Interleukin 6 (IL-6) is a proinflammatory cytokine that is secreted by cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and it is widely recognized as a negative prognostic factor. The purpose of this study was to analyze the correlations between the olfactory scores determined by psychophysical tests and the serum levels of IL-6 in patients affected by coronavirus disease 2019 (COVID-19) METHODS: Patients underwent psychophysical olfactory assessment with Connecticut Chemosensory Clinical Research Center test and IL-6 plasma level determination within 10 days of the clinical onset of COVID-19.
RESULTS RESULTS
Seventy-four COVID-19 patients were included in this study. COVID-19 staged as mild in 34 patients, moderate in 26 and severe in 14 cases. There were no significant differences in olfactory scores across the different COVID-19 severity groups. In the patient series, the median plasma level of IL-6 was 7.7 pg/mL (IQR 3.7-18.8). The concentration of IL-6 was found to be significantly correlated with the severity of COVID-19 with a directly proportional relationship. The correlation between IL-6 plasma concentrations and olfactory scores was weak (r
CONCLUSIONS CONCLUSIONS
In COVID-19 patients, psychophysical olfactory scores did not show significant correlations with the plasma levels of a well-recognized negative prognostic factor such as IL-6. This observation casts some shadows on the positive prognostic value of olfactory dysfunctions.

Identifiants

pubmed: 33983525
doi: 10.1007/s00405-021-06868-5
pii: 10.1007/s00405-021-06868-5
pmc: PMC8117453
doi:

Substances chimiques

IL6 protein, human 0
Interleukin-6 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

811-816

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021. The Author(s).

Références

J Laryngol Otol. 2020 Dec;134(12):1123-1127
pubmed: 33190655
Head Neck. 2020 Jun;42(6):1252-1258
pubmed: 32342566
Eur Arch Otorhinolaryngol. 1995;252 Suppl 1:S61-3
pubmed: 7734976
J Laryngol Otol. 2020 Jul;134(7):571-576
pubmed: 32605666
Chem Senses. 2020 Oct 9;45(7):609-622
pubmed: 32564071
Int Forum Allergy Rhinol. 2020 Sep;10(9):1103-1104
pubmed: 32342636
Front Med (Lausanne). 2020 Dec 02;7:589409
pubmed: 33344476
Pathogens. 2020 Jul 31;9(8):
pubmed: 32752123
Eur Arch Otorhinolaryngol. 2021 Aug;278(8):2851-2859
pubmed: 33452919
JAMA. 2020 May 26;323(20):2089-2090
pubmed: 32320008
JAMA Otolaryngol Head Neck Surg. 2013 Jul;139(7):728-34
pubmed: 23868430
ACS Chem Neurosci. 2020 Aug 5;11(15):2152-2155
pubmed: 32673476
Front Immunol. 2020 Jun 16;11:1446
pubmed: 32612617
J Immunol. 2006 Jul 1;177(1):642-50
pubmed: 16785562
Int Forum Allergy Rhinol. 2020 Aug;10(8):944-950
pubmed: 32301284
Lancet. 2020 Jul 18;396(10245):166
pubmed: 32659210
J Clin Virol. 2020 Jun;127:104370
pubmed: 32344321
J Investig Allergol Clin Immunol. 2020;30(5):346-357
pubmed: 32554337
Rhinology. 2021 Feb 1;59(1):21-25
pubmed: 33290446
Med Hypotheses. 2020 Oct;143:109881
pubmed: 32474381
ACS Chem Neurosci. 2020 Jul 1;11(13):1909-1913
pubmed: 32525657
Head Neck. 2020 Jul;42(7):1570-1576
pubmed: 32357379
J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4
pubmed: 32425269
Head Neck. 2020 Jul;42(7):1560-1569
pubmed: 32437022
Neuroscientist. 2002 Jun;8(3):268-75
pubmed: 12061506
Eur J Neurosci. 2001 Jul;14(2):327-41
pubmed: 11553283
Pathogens. 2021 Jan 12;10(1):
pubmed: 33445604
Chem Senses. 2021 Jan 1;46:
pubmed: 33575808
J Med Virol. 2020 Nov;92(11):2283-2285
pubmed: 32343429
J Infect. 2020 Apr;80(4):401-406
pubmed: 32112886
Otolaryngol Head Neck Surg. 2020 Jul;163(1):114-120
pubmed: 32423357
Am J Kidney Dis. 2008 Jul;52(1):102-10
pubmed: 18423810
ACS Chem Neurosci. 2020 Sep 2;11(17):2774-2781
pubmed: 32786309
J Laryngol Otol. 2020 Aug;134(8):703-709
pubmed: 32782030
J Otolaryngol Head Neck Surg. 2020 Aug 6;49(1):56
pubmed: 32762737
Rev Med Virol. 2020 Nov;30(6):1-9
pubmed: 32845568
Otolaryngol Head Neck Surg. 2020 Jul;163(1):12-15
pubmed: 32366160
Chem Senses. 2020 Dec 5;45(9):865-874
pubmed: 33245136
Int Forum Allergy Rhinol. 2020 Jul;10(7):926
pubmed: 32395917
Int Forum Allergy Rhinol. 2020 Jul;10(7):821-831
pubmed: 32329222

Auteurs

Luigi Angelo Vaira (LA)

Maxillofacial Surgery Operative Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Viale San Pietro 43/B, 07100, Sassari, Italy. lavaira@uniss.it.
Biomedical Science PhD School, Biomedical Science Department, University of Sassari, Sassari, Italy. lavaira@uniss.it.

Andrea De Vito (A)

Infectious and Tropical Diseases Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.

Giovanna Deiana (G)

Biomedical Science PhD School, Biomedical Science Department, University of Sassari, Sassari, Italy.
Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.

Chiara Pes (C)

Internal Medicine Department, University Hospital of Sassari, Sassari, Italy.
Neuro-COVID Department, University Hospital of Sassari, Sassari, Italy.

Federica Giovanditto (F)

Maxillofacial Surgery Operative Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Viale San Pietro 43/B, 07100, Sassari, Italy.
Onco-COVID Department, University Hospital of Sassari, Sassari, Italy.

Vito Fiore (V)

Infectious and Tropical Diseases Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.

Jerome R Lechien (JR)

COVID-19 Task Force of the Young-Otolaryngologists of the International Federation of Oto-Rhino-Laryngological Societies (YO-IFOS), Paris, France.
Department of Human and Experimental Oncology, Faculty of Medicine UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.

Serge-Daniel Le Bon (SD)

Department of Otorhinolaryngology, CHU Saint-Pierre, Brussels, Belgium.

Sven Saussez (S)

COVID-19 Task Force of the Young-Otolaryngologists of the International Federation of Oto-Rhino-Laryngological Societies (YO-IFOS), Paris, France.
Department of Human and Experimental Oncology, Faculty of Medicine UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.

Giordano Madeddu (G)

Infectious and Tropical Diseases Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.

Sergio Babudieri (S)

Infectious and Tropical Diseases Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.

Antonio Pazzola (A)

Onco-COVID Department, University Hospital of Sassari, Sassari, Italy.

Franco Bandiera (F)

Internal Medicine Department, University Hospital of Sassari, Sassari, Italy.
Neuro-COVID Department, University Hospital of Sassari, Sassari, Italy.

Alessandro Giuseppe Fois (AG)

Respiratory Diseases Operative Unit, University Hospital of Sassari, Sassari, Italy.

Andrea Fausto Piana (AF)

Biomedical Science PhD School, Biomedical Science Department, University of Sassari, Sassari, Italy.
Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.

Claire Hopkins (C)

King's College, London, UK.

Giacomo De Riu (G)

Maxillofacial Surgery Operative Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Viale San Pietro 43/B, 07100, Sassari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH